The impact of paricalcitol on left ventricular hypertrophy

Contributions to Nephrology

Volumn 171, Issue , 2011, Pages 161-165

  Cozzolino, Mario ^a   Ronco, Claudio ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN BORTOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL RECEPTOR; ERGOCALCIFEROL; PARICALCITOL;

ANIMAL; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DRUG EFFECT; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY DISEASE; PHYSIOLOGY; VITAMIN D DEFICIENCY;

ANIMALS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; ERGOCALCIFEROLS; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; RECEPTORS, CALCITRIOL; VITAMIN D DEFICIENCY;

EID: 79958168695     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000327170     Document Type: Article

References (23)

1. Berl T, Henrich W: Kidney- heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 2006;1:8-18.
2. Hage FG, Venkataraman R, Zoghbi GJ, et al: The scope of coronary heart disease in patients with chronic kidney disease. J Am Coll Cardiol 2009;53:2129-2140.
3. Cozzolino M, Ketteler M, Zehnder D: The vitamin D system: a crosstalk between the heart and kidney. Eur J Heart Fail 2010 Oct;12:1031-1041.
4. Levin A, Bakris GL, Molitch M, et al: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-38. (Pubitemid 44967731)
5. Giovannucci E, Liu Y, Hollis BW, Rimm EB: 25- hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008;168:1174-1180. (Pubitemid 351831400)
6. Autier P, Gandini S: Vitamin D supplementation and total mortality: a meta- analysis of randomized controlled trials. Arch Intern Med 2007;167:1730-1737. (Pubitemid 47403059)
7. Teng M, Wolf M, Lowrie E, et al: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-456. (Pubitemid 36910023)
8. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006;70:1858-1865. (Pubitemid 44684819)
9. Wolf M, Shah A, Gutierrez O, et al: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007;72:1004-1013. (Pubitemid 47530570)
10. Wolf M, Betancourt J, Chang Y, et al: Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol 2008;19:1379-1388.
11. Shoben AB, Rudser KD, de Boer IH, et al: Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008;19:1613-1619.
12. Cozzolino M, Fallabrino G, Pasho S, et al: Importance of vitamin D receptor activation in clinical practice. Contrib Nephrol 2009;163:213-218.
13. Ronco C, Cozzolino M: Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes. Heart Fail Rev 2011, E- pub ahead of print.
14. Wang TJ, Pencina MJ, Booth SL, et al: Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503-511.
15. Dobnig H, Pilz S, Scharnagl H, et al: Independent association of low serum 25 hydroxyvitamin D and 1,25- dihydroxyvitamin D levels with all- cause and cardiovascular mortality. Arch Intern Med 2008;168:1340-1349. (Pubitemid 351930842)
16. Kong J, Qiao G, Zhang Z, et al: Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int 2008;74:1577-1581.
17. Li YC, Kong J, Wei M, et al: 1,25- Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin- angiotensin system. J Clin Invest 2002;110:229-238. (Pubitemid 34787360)
18. Xiang W, Kong J, Chen S, et al: Cardiac hypertrophy in vitamin D receptor knockout mice: role of systemic and cardiac renin- angiotensin systems. Am J Physiol Endocrinol Metab 2005;288:125-132.
19. Bodyak N, Ayus JC, Achinger S, et al: Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt- sensitive animals. Proc Natl Acad Sci USA 2007;104:16810-16815. (Pubitemid 350210947)
20. London GM, Guerin AP, Verbeke FH, et al: Mineral metabolism and arterial functions in end- stage renal disease: potential role of 25- hydroxyvitamin D deficiency. J Am Soc Nephrol 2007;18:613-620. (Pubitemid 46193327)
21. Cozzolino M, Ciceri P, Volpi EM, et al: Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease. Blood Purif 2009;27:338-344.
22. Cozzolino M, Brandenburg V: Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the 'U'. Clin Nephrol 2009;71:593-601.
23. Thadhani R, Appelbaum E, Chang Y, et al: Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. Am J Nephrol 2011;33:139-149.